
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. is positioned favorably due to its advanced lead product candidate, oral (Z)-endoxifen, which is currently in Phase 2 clinical development for treating and preventing breast cancer, suggesting significant growth potential. The company's ongoing clinical trials are progressing well, and positive outcomes from these studies are expected to serve as strong catalysts for stock performance. Furthermore, the current valuation reflects a balance between the inherent high risks and notable growth prospects, indicating a compelling investment opportunity moving forward.
Bears say
Atossa Therapeutics reported a net loss of $10.9 million, translating to an earnings per share (EPS) of $(1.27), which was worse than both internal and consensus estimates of $(1.05). The company has historically faced significant financial losses, previously reporting a net loss of $8.7 million with an EPS of $(0.07), indicating a trend of widening deficits. Several risks further contribute to a negative outlook, including liquidity challenges, potential failures in demonstrating the safety and efficacy of product candidates, difficulties in obtaining regulatory approvals, and various external macroeconomic factors.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares